Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol)

Journal PubWeight™ 29236.62‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. 1997 29.02
2 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. 2007 25.52
3 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. 2006 25.12
4 Final version of 2009 AJCC melanoma staging and classification. 2009 23.08
5 Supervised risk predictor of breast cancer based on intrinsic subtypes. 2009 22.22
6 Revised response criteria for malignant lymphoma. 2007 22.19
7 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. 2008 20.89
8 Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. 2006 20.28
9 The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. 1993 18.75
10 Response criteria for phase II studies of supratentorial malignant glioma. 1990 18.71
11 Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. 2008 18.54
12 Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. 2003 17.67
13 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. 1999 17.43
14 Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. 2008 17.30
15 Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. 2010 17.13
16 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. 2000 16.83
17 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. 2006 16.25
18 Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. 2009 15.23
19 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. 2008 15.17
20 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. 2003 15.10
21 One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. 2008 15.05
22 Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. 2010 14.79
23 American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. 2010 14.41
24 American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. 2007 14.29
25 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. 2009 14.15
26 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. 2002 13.81
27 Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. 2009 13.52
28 Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. 2010 13.03
29 Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. 2004 12.89
30 Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. 2005 12.88
31 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. 2003 12.82
32 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. 2007 12.62
33 Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. 2013 12.57
34 Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. 2003 12.48
35 World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. 1999 12.42
36 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. 2003 12.24
37 Publication bias: the case for an international registry of clinical trials. 1986 12.14
38 Human papillomavirus and rising oropharyngeal cancer incidence in the United States. 2011 12.10
39 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. 1999 11.78
40 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. 2007 11.77
41 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. 2008 11.73
42 Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. 2013 11.68
43 Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. 2001 11.35
44 Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. 2003 11.33
45 International staging system for multiple myeloma. 2005 11.29
46 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. 2006 11.26
47 Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. 2003 11.22
48 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. 1999 11.18
49 American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. 2006 11.07
50 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. 2007 11.04
Next 50